JAMA· 2012Q1

One vs Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor

Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, Jörg T. Hartmann et al.

972citations
Q1SCImago
2012year

Short summary

Three years of adjuvant imatinib significantly improved recurrence-free survival (RFS) and overall survival in patients with high-risk gastrointestinal stromal tumors (GIST) compared to one year of treatment.

AI-generated from the title and abstract; the full text is not read.

TakeawaysIn the app

Key pointsIn the app

Ask the paperIn the app

The rest is in the Pofolia app

Takeaways, key points and questions to the paper; new summaries every day for your field. Free.

Get it on Google Play Download on the App Store

Field: Gastroenterology

GastroenterologyMedicine